More info…
Lightlake Therapeutics Inc has acquired US Patent 5,587,381, entitled: ‘Method for terminating methadone maintenance through extinction of the opiate-taking responses’, using an opioid antagonist as treatment. The Patent also covers treatment for addiction to other legally available opioids and to stimulant drugs such as Cocaine and Amphetamines.
Lightlake acquires US Patent for method of terminating methadone maintenance
Previous post: Lightlake acquires US Patent for method of terminating methadone maintenance
Next post: Anti-addiction pill a you-pay
